Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:20 PM
Ignite Modification Date:
2025-12-24 @ 11:20 PM
NCT ID:
NCT00019656
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed solid tumor, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, myelodysplastic syndromes, or Hodgkin's lymphoma that has no effective standard therapeutic option but requires systemic therapy
* No history of CNS neoplasms
* For prostate cancer:
* Tumor progression during blockade of testicular and adrenal androgens
* At least 4 weeks since prior flutamide or other antiandrogens without disease improvement
* Leuprolide or other gonadotropin-releasing hormones should be maintained in patients without an orchiectomy
* Testosterone in the castrate range
* For breast cancer:
* At least 4 weeks since any prior hormonal therapy with evidence of disease progression
PATIENT CHARACTERISTICS:
Age:
* Over 18
Performance status:
* ECOG 0-2
Life expectancy:
* Not specified
Hematopoietic:
* Platelet count greater than 50,000/mm\^3
* Absolute granulocyte count greater than 500/mm\^3
* Hemoglobin at least 9.0 g/dL
Hepatic:
* Bilirubin no greater than 1.5 mg/dL
* SGOT and SGPT no greater than 2.5 times normal
Renal:
* Creatinine no greater than 1.5 mg/dL OR
* Creatinine clearance at least 60 mL/min
Cardiovascular:
* No history of unstable or newly diagnosed angina pectoris
* No myocardial infarction within the past 6 months
* No New York Heart Association class II-IV heart disease
Other:
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* HIV negative
* No recent acute or chronic gastrointestinal conditions (e.g., stomach ulcer or enteritis) that might affect tolerability or drug absorption
* No allergic reaction to any medication with a structure similar to perifosine
* No pre-existing retinal disease or pathologic baseline electrooculogram
* No cataracts that would interfere with normal vision or require medical intervention
* No other serious concurrent illness that would preclude assessment of drug effect
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
* At least 2 months since prior UCN-01
* More than 3 months since prior suramin
Endocrine therapy:
* See Disease Characteristics
* No concurrent corticosteroids except for physiological replacement or as antiemetics
Radiotherapy:
* At least 4 weeks since prior radiotherapy (6 weeks for bone-seeking radioisotopes) and recovered
Surgery:
* See Disease Characteristics
Other:
* No other concurrent antineoplastic therapies
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00019656
Study Brief:
Protocol Section:
NCT00019656